Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Young patients with myelofibrosis have distinct clinicomolecular features, favorable prognosis, and commonly exhibit inflammatory comorbidities.

Annals of hematology - 1 Jan 2024

Horvat Nathan P, Abdallah Enas F, Xie Zhuoer, Al Ali Najla, Yun Seongseok, Walker Alison, Padron Eric, Sallman David, Chan Onyee, Lancet Jeffrey, Komrokji Rami, Kuykendall Andrew T

Abstract excerpt

Myelofibrosis (MF) is commonly diagnosed in older individuals and has not been extensively studied in young patients. Given the infrequent diagnosis in young patients, analyzing this cohort may identify factors that predict for disease development/progression. We retrospectively analyzed clinical/genomic characteristics, treatments, and outcomes of patients with MF aged 18-50 years (YOUNG) at diagnosis....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Comorbidity

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Hematopoietic Stem Cell Transplantation

Share to Mutation

Share to Primary Myelofibrosis

Share to Prognosis

Share to Young Adult

Source

Identifiers

PMID: 38030891
DOI: 10.1007/s00277-023-05564-0

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Young patients with myelofibrosis have distinct clinicomolecular features, favorable prognosis, and commonly exhibit inflammatory comorbidities.PMID 38030891Read ↗

A provider's guide to primary myelofibrosis: pathophysiology, diagnosis, and management.Semantic proximity Read ↗

Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management.Semantic proximity Read ↗

Myelofibrosis biology and contemporary management.Semantic proximity Read ↗

Myeloproliferative neoplasms in the young: Mayo Clinic experience with 361 patients age 40 years or younger.Semantic proximity Read ↗

Myeloproliferative Neoplasms in Children, Adolescents, and Young Adults.Semantic proximity Read ↗

Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis.Semantic proximity Read ↗

Association of Myelofibrosis Phenotypes with Clinical Manifestations, Molecular Profiles, and TreatmentsSemantic proximity Read ↗

Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management.Semantic proximity Read ↗

Clinical Characteristics and Outcomes of Patients with Primary and Secondary Myelofibrosis According to the Genomic Classification Using Targeted Next-Generation SequencingSemantic proximity Read ↗

Management of Myelofibrosis: from Diagnosis to New Target Therapies.Semantic proximity Read ↗

Myeloproliferative neoplasms in the young: unique disease patterns and therapeutic strategies.Semantic proximity Read ↗

Epidemiology and disease characteristics of myelofibrosis: a comparative analysis between Italy and global perspectivesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.